Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

ABSTRACT:

Background

A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.

Methods

In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients with advanced or metastatic NSCLC with a confirmed MET exon 14 skipping mutation. The primary end point was the objective response by independent review among patients who had undergone at least 9 months of follow-up. The response was also analyzed according to whether the presence of a MET exon 14 skipping mutation was detected on liquid biopsy or ti

SUBMITTER: Paik PK 

PROVIDER: S-EPMC8422679 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature